Pfizer Says Hympavzi Reduced Bleeds by 93% Compared With On-Demand Treatment in Phase-3 Study
MT Newswires Live
Dec 08
Pfizer (PFE) said Friday that results from a phase-3 study evaluating Hympavzi in adults and adolescents with hemophilia A or B with inhibitors showed a 93% reduction in bleeding compared with on-demand treatment with bypassing agents.
The company said that the mean treated annualized bleeding rate was 1.39 in patients who were dosed with Hympavzi, compared with 19.78 in those given the on-demand treatment.
The results were consistent across hemophilia type, age, and geographies, Pfizer said.
Pfizer said that Hympavzi was administered with a straightforward, once-weekly subcutaneous injection.
Pfizer said it has submitted the data to the US Food and Drug Administration and the European Medicines Agency for review.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.